Company Of The Day: Roche Holdings

October 19th, 2022 by Trefis Team
+1.56%
Upside
24.58
Market
24.96
Trefis
NWSA: News logo
NWSA
News

What?

Roche Holdings (OTCMKTS: RHHBY) Q3 2022 revenue declined 6% to CHF 14.74 billion ($14.8 billion).

Why?

Relevant Articles
  1. Should You Pick General Electric Stock At $165?
  2. What’s Next For JetBlue Stock After A Sharp 19% Fall Post Q1 Results?
  3. Is Kimberly-Clark Stock Fairly Valued At $135 After A Solid Q1?
  4. How Will AMD’s AI Business Fare In Q1?
  5. Up 9% Year To Date, Will Chevron’s Gains Continue Following Q1 Results?
  6. Earnings Beat In The Cards For Honeywell?

A decline in demand for Covid-19 diagnostics and treatments outweighed the gains that the company made with its hemophilia and multiple sclerosis drugs.

So What?

Roche stock was down by almost 1.5% in early trading on Tuesday although it recovered later in the day.

See Our Complete Analysis For Roche

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Oct 2022
MTD [1]		 2022
YTD [1]		 2017-22
Total [2]
 RHHBY Return 1% -20% 44%
 S&P 500 Return 4% -22% 66%
 Trefis Multi-Strategy Portfolio 3% -24% 201%

[1] Month-to-date and year-to-date as of 10/19/2022
[2] Cumulative total returns since the end of 2016

 

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates